LAVA Therapeutics (LVTX)
(Delayed Data from NSDQ)
$1.75 USD
-0.05 (-2.78%)
Updated Aug 7, 2024 03:59 PM ET
After-Market: $1.73 -0.02 (-1.14%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LVTX 1.75 -0.05(-2.78%)
Will LVTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LVTX
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
LVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimates
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
Evogene (EVGN) Reports Q2 Loss, Lags Revenue Estimates
Other News for LVTX
LAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Underpin Buy Rating
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
LAVA Therapeutics Shareholders Approve Key Resolutions
LAVA Announces Annual Meeting of Shareholders
LAVA Therapeutics’ Innovative Gammabody® Cancer Therapy